Department of Neurology, Acıbadem University School of Medicine, Istanbul, Turkey.
Cytokine. 2012 Aug;59(2):400-2. doi: 10.1016/j.cyto.2012.05.004. Epub 2012 May 30.
Therapeutic effect of interferon-β (IFN-β) treatment has been associated with modulation of the balance between Th1, Th17, Th2 and regulatory T (Treg) cells, whereas the impact of disease modifying drugs on Th9-immunity in multiple sclerosis (MS) has not been studied. To investigate the short-term effects of IFN-β treatment on cytokines in MS, we determined serum levels of IL-17, IL-23, IL-10, IL-4, IFN-γ, IL-9 and TGF-β in relapsing remitting MS patients before and 2 months after IFN-β treatment by ELISA. MS patients showed increased IL-17, IL-23 and IL-4 levels and decreased IL-9 levels as compared to healthy controls. IFN-β treatment only reduced IL-17 and IL-23 levels, whereas the levels of other cytokines remained unchanged. IFN-β treatment appears to exert its earliest therapeutic effect on Th17-immunity. The influence of IL-9 on MS pathogenesis needs to be further studied.
干扰素-β（IFN-β）治疗的疗效与 Th1、Th17、Th2 和调节性 T（Treg）细胞之间平衡的调节有关，而疾病修正药物对多发性硬化症（MS）中 Th9 免疫的影响尚未得到研究。为了研究 IFN-β治疗对 MS 中细胞因子的短期影响，我们通过 ELISA 在 IFN-β治疗前和治疗后 2 个月测定了复发缓解型 MS 患者的血清中 IL-17、IL-23、IL-10、IL-4、IFN-γ、IL-9 和 TGF-β的水平。与健康对照组相比，MS 患者的 IL-17、IL-23 和 IL-4 水平升高，而 IL-9 水平降低。IFN-β治疗仅降低了 IL-17 和 IL-23 的水平，而其他细胞因子的水平保持不变。IFN-β 治疗似乎对 Th17 免疫产生最早的治疗效果。IL-9 对 MS 发病机制的影响需要进一步研究。
